-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is only for medical professionals to read for reference.
How to choose anti-flu drugs? Influenza (flu) is an acute respiratory infectious disease caused by influenza virus (flu virus).
Due to the variability and unpredictability of influenza virus (mainly influenza A virus), it often causes influenza outbreaks and even Cause a global pandemic
.
The results of the national influenza surveillance show that every October in China successively enters the influenza winter and spring season
.
Influenza has a rapid onset, although most of them are self-limiting, but some patients develop severe cases due to complications such as pneumonia or aggravation of underlying diseases, and a few cases progress rapidly and may die due to complications
.
Neuraminidase inhibitor (NAI) is currently a commonly used anti-influenza virus drug, effective against influenza A and B.
There are currently three types of NAI on the market in China: Peramivir, Oseltamivir Phosphate and Zana Miwe
.
Today Xiaoyao will summarize the similarities and differences of these three drugs for everyone
.
1.
Differences in indications and clinical selection characteristics Table 1 Preparation characteristics and clinical selection characteristics of commonly used neuraminidase inhibitors 2.
Differences in dosage form Table 2 Therapeutic dosage and usage of common neuraminidase inhibitors in adults and children [3] Three points for attention difference Table 3 Commonly used neuraminidase inhibitors for clinical use points Four point of attention for use in special populations 1 Children, oseltamivir phosphate is recommended in China for the treatment of influenza for children under 1 year old, Namivir is used in the treatment of children >7 years of age
.
Peramivir is the first approved intravenous NAI for use in people of all ages
.
2For pregnant women, please use NAI anti-influenza virus treatment.
No serious adverse reactions to pregnant women and fetuses have been found
.
5.
Summary Neuraminidase inhibitors can effectively prevent and relieve flu symptoms.
In the treatment of patients with flu-like symptoms, it is recommended to use them within 24 to 48 hours of flu symptoms in order to more effectively exert antiviral effects and effectively relieve symptoms , Significantly shorten the course of the disease, but the medication indications should be strictly controlled to avoid drug abuse, so as to avoid the emergence of drug resistance
.
Reference materials: [1] Consensus of Chinese experts on the treatment and prevention of influenza antiviral drugs[J].
Chinese Medical Journal,2016,96(02):85-90.
[2] Zanamivir, Oseltamivir , Peramivir instructions
.
[3] Influenza diagnosis and treatment plan (2020 version)
.
[4] National Respiratory Diseases Clinical Medicine Research Center, Respiratory Group of Pediatrics Branch of Chinese Medical Association.
Expert consensus on diagnosis and treatment of influenza in children (2020 edition) [J].
Chinese Journal of Practical Pediatrics, 2020, 35(17): 1281-1288.
[5] Respiratory Group of Pediatrics Branch of Chinese Medical Association, Editorial Committee of Chinese Journal of Practical Pediatrics.
Expert consensus on diagnosis and treatment of influenza in children (2015 edition)[J].
Chinese Journal of Practical Pediatrics, 2015, 30(17):1296-1303.
How to choose anti-flu drugs? Influenza (flu) is an acute respiratory infectious disease caused by influenza virus (flu virus).
Due to the variability and unpredictability of influenza virus (mainly influenza A virus), it often causes influenza outbreaks and even Cause a global pandemic
.
The results of the national influenza surveillance show that every October in China successively enters the influenza winter and spring season
.
Influenza has a rapid onset, although most of them are self-limiting, but some patients develop severe cases due to complications such as pneumonia or aggravation of underlying diseases, and a few cases progress rapidly and may die due to complications
.
Neuraminidase inhibitor (NAI) is currently a commonly used anti-influenza virus drug, effective against influenza A and B.
There are currently three types of NAI on the market in China: Peramivir, Oseltamivir Phosphate and Zana Miwe
.
Today Xiaoyao will summarize the similarities and differences of these three drugs for everyone
.
1.
Differences in indications and clinical selection characteristics Table 1 Preparation characteristics and clinical selection characteristics of commonly used neuraminidase inhibitors 2.
Differences in dosage form Table 2 Therapeutic dosage and usage of common neuraminidase inhibitors in adults and children [3] Three points for attention difference Table 3 Commonly used neuraminidase inhibitors for clinical use points Four point of attention for use in special populations 1 Children, oseltamivir phosphate is recommended in China for the treatment of influenza for children under 1 year old, Namivir is used in the treatment of children >7 years of age
.
Peramivir is the first approved intravenous NAI for use in people of all ages
.
2For pregnant women, please use NAI anti-influenza virus treatment.
No serious adverse reactions to pregnant women and fetuses have been found
.
5.
Summary Neuraminidase inhibitors can effectively prevent and relieve flu symptoms.
In the treatment of patients with flu-like symptoms, it is recommended to use them within 24 to 48 hours of flu symptoms in order to more effectively exert antiviral effects and effectively relieve symptoms , Significantly shorten the course of the disease, but the medication indications should be strictly controlled to avoid drug abuse, so as to avoid the emergence of drug resistance
.
Reference materials: [1] Consensus of Chinese experts on the treatment and prevention of influenza antiviral drugs[J].
Chinese Medical Journal,2016,96(02):85-90.
[2] Zanamivir, Oseltamivir , Peramivir instructions
.
[3] Influenza diagnosis and treatment plan (2020 version)
.
[4] National Respiratory Diseases Clinical Medicine Research Center, Respiratory Group of Pediatrics Branch of Chinese Medical Association.
Expert consensus on diagnosis and treatment of influenza in children (2020 edition) [J].
Chinese Journal of Practical Pediatrics, 2020, 35(17): 1281-1288.
[5] Respiratory Group of Pediatrics Branch of Chinese Medical Association, Editorial Committee of Chinese Journal of Practical Pediatrics.
Expert consensus on diagnosis and treatment of influenza in children (2015 edition)[J].
Chinese Journal of Practical Pediatrics, 2015, 30(17):1296-1303.